Tus-Pharmaceutical Group Résultats passés
Passé contrôle des critères 0/6
Tus-Pharmaceutical Group's earnings have been declining at an average annual rate of -27%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.1% per year.
Informations clés
-27.0%
Taux de croissance des bénéfices
-27.0%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 7.1% |
| Rendement des fonds propres | -1.4% |
| Marge nette | -2.8% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Tus-Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 346 | -10 | 167 | 13 |
| 30 Jun 24 | 361 | -5 | 172 | 13 |
| 31 Mar 24 | 381 | 10 | 177 | 12 |
| 31 Dec 23 | 405 | 25 | 176 | 13 |
| 30 Sep 23 | 389 | 9 | 168 | 15 |
| 30 Jun 23 | 385 | 13 | 165 | 14 |
| 31 Mar 23 | 360 | 12 | 155 | 13 |
| 01 Jan 23 | 351 | 18 | 145 | 13 |
| 30 Sep 22 | 321 | 12 | 145 | 10 |
| 30 Jun 22 | 308 | 18 | 136 | 10 |
| 31 Mar 22 | 315 | 27 | 131 | 9 |
| 01 Jan 22 | 301 | 35 | 125 | 8 |
| 30 Sep 21 | 315 | 42 | 128 | 9 |
| 30 Jun 21 | 308 | 38 | 126 | 9 |
| 31 Mar 21 | 291 | 34 | 119 | 10 |
| 31 Dec 20 | 275 | 23 | 117 | 10 |
| 30 Sep 20 | 277 | 44 | 111 | 9 |
| 30 Jun 20 | 274 | 41 | 114 | 8 |
| 31 Mar 20 | 288 | 41 | 120 | 9 |
| 31 Dec 19 | 315 | 42 | 124 | 9 |
| 30 Sep 19 | 271 | -10 | 128 | 10 |
| 30 Jun 19 | 241 | -26 | 129 | 9 |
| 31 Mar 19 | 215 | -33 | 121 | 9 |
| 31 Dec 18 | 186 | -38 | 115 | 7 |
| 30 Sep 18 | 203 | 24 | 133 | 6 |
| 30 Jun 18 | 234 | 40 | 140 | 6 |
| 31 Mar 18 | 281 | 45 | 157 | 7 |
| 31 Dec 17 | 293 | 50 | 164 | 6 |
| 30 Sep 17 | 295 | 74 | 143 | 4 |
| 30 Jun 17 | 298 | 74 | 139 | 3 |
| 31 Mar 17 | 279 | 69 | 133 | 0 |
| 31 Dec 16 | 301 | 72 | 137 | 0 |
| 30 Sep 16 | 295 | 3 | 128 | 0 |
| 30 Jun 16 | 298 | 23 | 114 | 0 |
| 31 Mar 16 | 300 | 26 | 120 | 0 |
| 31 Dec 15 | 295 | 22 | 121 | 0 |
| 30 Sep 15 | 285 | -56 | 177 | 0 |
| 30 Jun 15 | 269 | -76 | 186 | 0 |
| 31 Mar 15 | 235 | -78 | 169 | 0 |
| 31 Dec 14 | 203 | -86 | 160 | 0 |
| 30 Sep 14 | 174 | -164 | 163 | 0 |
| 30 Jun 14 | 175 | -180 | 171 | 0 |
| 31 Mar 14 | 215 | -177 | 191 | 0 |
| 31 Dec 13 | 256 | -164 | 195 | 0 |
Des revenus de qualité: 000590 is currently unprofitable.
Augmentation de la marge bénéficiaire: 000590 is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 000590 is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.
Accélération de la croissance: Unable to compare 000590's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: 000590 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendement des fonds propres
ROE élevé: 000590 has a negative Return on Equity (-1.42%), as it is currently unprofitable.